Compounds > 2-(3',5'-di-tert-butyl-2'-hydroxyphenyl)-5-chlorobenzotriazole
Page last updated: 2024-12-07

2-(3',5'-di-tert-butyl-2'-hydroxyphenyl)-5-chlorobenzotriazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-(3',5'-di-tert-butyl-2'-hydroxyphenyl)-5-chlorobenzotriazole, also known as UV-328, is a hindered phenolic antioxidant commonly used as a UV stabilizer in polymers. It effectively absorbs ultraviolet radiation, preventing degradation and discoloration of the polymer. This compound works by forming a stable radical intermediate after reacting with free radicals. Its effectiveness is attributed to the presence of the tert-butyl groups, which sterically hinder the molecule, protecting it from reacting with other molecules and prolonging its antioxidant activity. The compound is typically synthesized through a multi-step reaction involving condensation of 5-chloro-2-aminobenzotriazole with 3,5-di-tert-butyl-2-hydroxybenzaldehyde, followed by oxidation. UV-328 finds application in various industries, including plastics, coatings, and adhesives, as a UV stabilizer to enhance the durability and longevity of materials.'

2-(3',5'-di-tert-butyl-2'-hydroxyphenyl)-5-chlorobenzotriazole: a sunscreening agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID77470
CHEBI ID169475
SCHEMBL ID29241
MeSH IDM0500022

Synonyms (70)

Synonym
2,4-di- t-butyl-6(5-chloro-2h-benzotriazol-2-yl)phenol
AC-15278
BIDD:ER0467
5-chloro-2-(3,5-di-tert-butyl-2-hydroxyphenyl)-2h-benzotriazole
2,4-ditert-butyl-6-(5-chlorobenzotriazol-2-yl)phenol
CHEBI:169475
17tje602rx ,
unii-17tje602rx
2-(5-chloro-2h-benzotriazol-2-yl)-4,6-di-tert-butylphenol
2-(3',5'-di-tert-butyl-2'-hydroxyphenyl)-5-chloro-2h-benzotriazole
2,4-di-tert-butyl-6-(5-chlorobenzotriazol-2-yl)phenol
einecs 223-383-8
phenol, 2-(5-chloro-2h-benzotriazol-2-yl)-4,6-bis(1,1-dimethylethyl)-
CBDIVE_008145
2,4-di-tert-butyl-6-(5-chloro-2h-benzotriazol-2-yl)phenol, 98%
3864-99-1
2,4-di-tert-butyl-6-(5-chloro-2h-benzotriazol-2-yl)phenol
STK051072
2,4-di-tert-butyl-6-(5-chloro-2-benzotriazolyl)phenol
5-chloro-2-(3,5-di-tert-butyl-2-hydroxyphenyl)benzotriazole
2-(3,5-di-tert-butyl-2-hydroxyphenyl)-5-chlorobenzotriazole
D1529
2-(3',5'-di-tert-butyl-2'-hydroxyphenyl)-5-chlorobenzotriazole
2,4-di-tert-butyl-6-(5-chlorobenzotriazol-2-yl) phenol
A824212
2,4-ditert-butyl-6-(5-chloro-2-benzotriazolyl)phenol
2,4-ditert-butyl-6-(5-chloranylbenzotriazol-2-yl)phenol
c20h24cln3o
AKOS005385757
2-(2'-hydroxy-3',5'-di-tert-butylphenyl)-5-chlorobenzotriazole
FT-0617276
uv-2
antioxidant 327
uv-327
la-34
phenol, 2,4-di-tert-butyl-6-(5-chloro-2h-benzotriazol-2-yl)-
2-(2'-hydroxy-3',5'-di-t-butyl phenyl)-5-chlorobenzotriazole
5-chloro-2-(2-hydroxy-3,5-di-tert-butylphenyl)2h-benzotriazole
2-(2'-hydroxy-3',5'-di-tertbutylphenyl)-5-chlorobenzotriazole
5-chloro-(2-hydroxy-3,5-di-tert-butylphenyl)-2h-benzotriazole
2-(2'-hydroxy-3',5'-di-t-butylphenyl)-5-chlorbenzotriazole
2,4-di-tert-butyl-6-(5-chloro-2h-benzo-triazol-2-yl)phenol
5-chloro-2-(2-hydroxy-3,5-di-tert-butylphenyl)-2h-benzotriazole
2-(2'-hydroxy-3',5'-di-t-butyl-phenyl)-5-chlorobenzotriazole
5-chloro-(2-hydroxy-3,5-di-tert-butyl-phenyl)-2h-benzotriazole
2-(2'-hydroxy-3',5'-di-t-butylphenyl)-5-chlorobenzotriazole
2-(2'-hydroxy-3',5'-di-tert-butylphenyl)-5-chlorobenzotriazol
2(2'-hydroxy-3',5'-di-tert-butylphenyl)-5-chlorobenzotriazol
tinuvin 327
5-chloro-2-(2-hydroxy-3,5-di-tert-butylphenyl)-2 h-benzotriazole
SCHEMBL29241
2,4-di-tert-butyl-6-(5-chloro-2h-benzo[d][1,2,3]triazol-2-yl)phenol
2,4-di-t-butyl-6-(5-chloro-2h-benzotriazol-2-yl)phenol
W-106471
2,4-di-tert-butyl-6-(5-chloro-2h-benzotriazol-2-yl)phenol, certified reference material, tracecert(r)
2-(3',5'-di-t-butyl-2'-hydroxyphenyl)-5-chlorobenzotriazole
2-(3,5-di-t-butyl-2-hydroxyphenyl)-5-chlorobenzotriazole
uvazol 237
DTXSID4038893
2,4-di-tert-butyl-6-(5-chloro-2h-1,2,3-benzotriazol-2-yl)phenol
mfcd00059706
AS-70325
2,4-di-tert-butyl-6-(5-chloro-2h-benzotriazol-2-yl)phenol, 8ci
2-(5-chloro-2h-benzotriazol-2-yl)-4,6-bis(1,1-dimethylethyl)phenol, 9ci
2-(2-hydroxy-3,5-di-tert-butyl)phenyl-5-chlorobenzotriazole
2-(2-hydroxy-3,5-di-tert-butylphenyl)-5-chlorobenzotriazole
D70556
Q27251940
2,4-di-tert-butyl-6-(5-chloro-2h-benzo-[d][1,2,3]triazol-2-yl)phenol
CS-0154920

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Previously, we showed that male rats had more than a 100 times higher susceptibility to the toxic effects of DBHCB than females."( Gender-related difference in the toxicity of ultraviolet absorber 2-(3',5'-di-tert-butyl-2'-hydroxyphenyl)-5-chlorobenzotriazole in rats.
Ema, M; Hirata-Koizumi, M; Hirose, A; Imai, T; Kamata, E; Matsuyama, T, 2008)		0.58

Dosage Studied

ExcerptRelevanceReference
" Male and female rats were dosed beginning 28 d before mating, and each female rat was mated with a male rat of the same dosage group."( Repeated-dose and reproductive toxicity of the ultraviolet absorber 2-(3',5'-di- tert-butyl-2'-hydroxyphenyl)-5-chlorobenzotriazole in rats.
Ema, M; Fukunishi, K; Hirata-Koizumi, M; Hirose, A; Kamata, E; Matsumoto, M, 2008)		0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
triazolesAn azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's1 (20.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
benzotriazole
benzotriazole: inhibitor of atmospheric metal corrosion; also component of motion picture film & Neva brake fluid. benzotriazole : The simplest member of the class of benzotriazoles that consists of a benzene nucleus fused to a 1H-1,2,3-triazole ring.		2.610benzotriazolesenvironmental contaminant;
xenobiotic
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		3.16501,2,3-triazole
ConditionIndicatedRelationship StrengthStudiesTrials
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.4420
Hypertrophy
General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).		02.0410
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		02.0410
Abnormalities, Drug-Induced
Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.		02.0310